Mevalonate-suppressive tocotrienols for cancer chemoprevention and adjuvant therapy

Tocotrienols: Vitamin E beyond Tocopherols, Second Edition

Volumn , Issue , 2012, Pages 135-150

  Mo, Huanbiao ^a   Elfakhani, Manal ^a   Shah, Anureet ^a   Yeganehjoo, Hoda ^a  

^a TEXAS WOMAN'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885359224     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b12502     Document Type: Chapter

References (129)

1. Adjei, A. A. 2001. Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer Inst. 93, 1062-1074.
2. Ahn, K. S., G. Sethi, K. Krishnan and B. B. Aggarwal. 2007. γ-Tocotrienol inhibits nuclear factor-κB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis. J. Biol. Chem. 282, 809-820.
3. Ali, H., A. B. Shirode, P. W. Sylvester and S. Nazzal. 2010. Preparation, characterization, and anticancer effects of simvastatin-tocotrienol lipid nanoparticles. Int. J. Pharm. 389, 223-231.
4. Anderson, K. M. and J. E. Harris. 2001. Selected features of nonendocrine pancreatic cancer. Exp. Biol. Med. (Maywood) 226, 521-537.
5. Ayoub, N. M., S. V. Bachawal and P. W. Sylvester. 2011. γ-Tocotrienol inhibits HGF-dependent mitogenesis and Met activation in highly malignant mammary tumour cells. Cell Prolif. 44, 516-526.
6. Bachawal, S. V., V. B. Wali and P. W. Sylvester. 2010. Combined γ-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells. Anticancer Res. 30, 429-437.
7. Barve, A., T. O. Khor, K. Reuhl, B. Reddy, H. Newmark and A. N. Kong. 2010. Mixed tocotrienols inhibit prostate carcinogenesis in TRAMP mice. Nutr. Cancer 62, 789-794.
8. Behery, F. A., A. Y. Elnagar, M. R. Akl, V. B. Wali, B. Abuasal, A. Kaddoumi, P. W. Sylvester and K. A. El Sayed. 2010. Redox-silent tocotrienol esters as breast cancer proliferation and migration inhibitors. Bioorg. Med. Chem. 18, 8066-8075.
9. Boucher, M. J., J. Morisset, P. H. Vachon, J. C. Reed, J. Laine and N. Rivard. 2000. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J. Cell. Biochem. 79, 355-369.
10. Campbell, S. E. et al. 2011. γ-Tocotrienol induces growth arrest through a novel pathway with TGFβ2 in prostate cancer. Free Radic. Biol. Med. 50, 1344-1354.
11. Chang, P. N., W. N. Yap, D. T. Lee, M. T. Ling, Y. C. Wong and Y. L. Yap. 2009. Evidence of γ-tocotrienol as an apoptosis-inducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cells. Nutr. Cancer 61, 357-366.
12. Cho, I. J., J. Y. Ahn, S. Kim, M. S. Choi and T. Y. Ha. 2008. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem. Biophys. Res. Commun. 367, 190-194.
13. Choi, Y. and J. Lee. 2009. Antioxidant and antiproliferative properties of a tocotrienol-rich fraction from grape seeds. Food Chem. 114, 1386-1390.
14. Comitato, R., K. Nesaretnam, G. Leoni, R. Ambra, R. Canali, A. Bolli, M. P. Marino and F. Virgili. 2009. A novel mechanism of natural vitamin E tocotrienol activity: Involvement of ERβ signal transduction. Am. J. Physiol. Endocrinol. Metab. 297, E427-E437.
15. Conte, C., A. Floridi, C. Aisa, M. Piroddi and F. Galli. 2004. γ-Tocotrienol metabolism and antiproliferative effect in prostate cancer cells. Ann. NY Acad. Sci. 1031, 391-394.
16. Correll, C. C., L. Ng and P. A. Edwards. 1994. Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem. 269, 17390-17393.
17. Dricu, A., M. Carlberg, M. Wang and O. Larsson. 1997. Inhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells: Role of down-regulation of the insulin-like growth factor 1 receptor in induction of apoptosis. Cancer Res. 57, 543-548.
18. Elangovan, S., T. C. Hsieh and J. M. Wu. 2008. Growth inhibition of human MDA-MB-231 breast cancer cells by δ-tocotrienol is associated with loss of cyclin D1/CDK4 expression and accompanying changes in the state of phosphorylation of the retinoblastoma tumor suppressor gene product. Anticancer Res. 28, 2641-2647.
19. Elnagar, A. Y., V. B. Wali, P. W. Sylvester and K. A. El Sayed. 2010. Design and preliminary structure-activity relationship of redox-silent semisynthetic tocotrienol analogues as inhibitors for breast cancer proliferation and invasion. Bioorg. Med. Chem. 18, 755-768.
20. End, D. W. et al. 2001. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 61, 131-137.
21. Fernandes, N. V., P. K. Guntipalli and H. Mo. 2010. d-δ-Tocotrienol-mediated cell cycle arrest and apoptosis in human melanoma cells. Anticancer Res. 30, 4937-4944.
22. Ferrara, N. 2002. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2, 795-803.
23. Ferrara, N., H. P. Gerber and J. LeCouter. 2003. The biology of VEGF and its receptors. Nat. Med. 9, 669-676.
24. Gelb, M. H. 1997. Protein prenylation, et cetera: Signal transduction in two dimensions. Science 275, 1750-1751.
25. Goldstein, J. L. and M. S. Brown. 1990. Regulation of the mevalonate pathway. Nature 343, 425-430.
26. Guthrie, N., A. Gapor, A. F. Chambers and K. K. Carroll. 1997. Inhibition of proliferation of estrogen receptornegative MDA-MB-435 and-positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination. J. Nutr. 127, 544S-548S.
27. Kip1. Cancer Res. 65, 4870-4880.
28. Harrison, L. E., D. C. Wojciechowicz, M. F. Brennan and P. B. Paty. 1998. Phenylacetate inhibits isoprenoid biosynthesis and suppresses growth of human pancreatic carcinoma. Surgery 124, 541-550.
29. He, L., H. Mo, S. Hadisusilo, A. A. Qureshi and C. E. Elson. 1997. Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J. Nutr. 127, 668-674.
30. Hiura, Y., H. Tachibana, R. Arakawa, N. Aoyama, M. Okabe, M. Sakai and K. Yamada. 2009. Specific accumulation of γ- and δ-tocotrienols in tumor and their antitumor effect in vivo. J. Nutr. Biochem. 20, 607-613.
31. Holcomb, B., M. Yip-Schneider and C. M. Schmidt. 2008. The role of nuclear factor κB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas 36, 225-235.
32. Hsieh, T. C., S. Elangovan and J. M. Wu. 2010a. Differential suppression of proliferation in MCF-7 and MDA-MB-231 breast cancer cells exposed to α-, γ- and δ-tocotrienols is accompanied by altered expression of oxidative stress modulatory enzymes. Anticancer Res. 30, 4169-4176.
33. Hsieh, T. C., S. Elangovan and J. M. Wu. 2010b. γ-Tocotrienol controls proliferation, modulates expression of cell cycle regulatory proteins and up-regulates quinone reductase NQO2 in MCF-7 breast cancer cells. Anticancer Res. 30, 2869-2874.
34. Hsieh, T. C. and J. M. Wu. 2008. Suppression of cell proliferation and gene expression by combinatorial synergy of EGCG, resveratrol and γ-tocotrienol in estrogen receptor-positive MCF-7 breast cancer cells. Int. J. Oncol. 33, 851-859.
35. Husain, K., R. A. Francois, S. Z. Hutchinson, A. M. Neuger, R. Lush, D. Coppola, S. Sebti and M. P. Malafa. 2009. Vitamin E δ-tocotrienol levels in tumor and pancreatic tissue of mice after oral administration. Pharmacology 83, 157-163.
36. Husain, K., R. A. Francois, T. Yamauchi, M. Perez, S. M. Sebti and M. P. Malafa. 2011. Vitamin E δ-tocotrienol augments the anti-tumor activity of gemcitabine and suppresses constitutive NFκB activation in pancreatic cancer. Mol. Cancer Ther. 10, 2363-2372.
37. Hussein, D. and H. Mo. 2009. d-δ-Tocotrienol-mediated suppression of the proliferation of human PANC-1, MIA PaCa2 and BxPC-3 pancreatic carcinoma cells. Pancreas 38, e124-e136.
38. Hutchison, C. J., J. M. Bridger, L. S. Cox and I. R. Kill. 1994. Weaving a pattern from disparate threads: Lamin function in nuclear assembly and DNA replication. J. Cell Sci. 107 (Pt 12), 3259-3269.
39. Inokuchi, H., H. Hirokane, T. Tsuzuki, K. Nakagawa, M. Igarashi and T. Miyazawa. 2003. Anti-angiogenic activity of tocotrienol. Biosci. Biotechnol. Biochem. 67, 1623-1627.
40. Inoue, A., K. Takitani, M. Koh, C. Kawakami, T. Kuno and H. Tamai. 2011. Induction of apoptosis by γ-tocotrienol in human cancer cell lines and leukemic blasts from patients: Dependency on Bid, cytochrome c, and caspase pathway. Nutr. Cancer 63, 763-770.
41. Ji, X., Z. Wang, A. Geamanu, F. H. Sarkar and S. V. Gupta. 2011. Inhibition of cell growth and induction of apoptosis in non-small cell lung cancer cells by δ-tocotrienol is associated with notch-1 down-regulation. J. Cell. Biochem. 112, 2773-2783.
42. Jiang, Q., X. Rao, C. Y. Kim, H. Freiser, Q. Zhang, Z. Jiang and G. Li. 2011. Gamma-tocotrienol induces apoptosis and autophagy in prostate cancer cells by increasing intracellular dihydrosphingosine and dihydroceramide. Int. J. Cancer 130, 685-693.
43. Jiang, X. and X. Wang. 2004. Cytochrome C-mediated apoptosis. Annu. Rev. Biochem. 73, 87-106.
44. Kannappan, R., J. Ravindran, S. Prasad, B. Sung, V. R. Yadav, S. Reuter, M. M. Chaturvedi and B. B. Aggarwal. 2010a. γ-Tocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of death receptors. Mol. Cancer Ther. 9, 2196-2207.
45. Kannappan, R., V. R. Yadav and B. B. Aggarwal. 2010b. γ-Tocotrienol but not γ-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents. J. Biol. Chem. 285, 33520-33528.
46. Kashiwagi, K., K. Harada, Y. Yano, I. Kumadaki, K. Hagiwara, J. Takebayashi, W. Kido, N. Virgona and T. Yano. 2008. A redox-silent analogue of tocotrienol inhibits hypoxic adaptation of lung cancer cells. Biochem. Biophys. Res. Commun. 365, 875-881.
47. Kashiwagi, K., N. Virgona, K. Harada, W. Kido, Y. Yano, A. Ando, K. Hagiwara and T. Yano. 2009. A redoxsilent analogue of tocotrienol acts as a potential cytotoxic agent against human mesothelioma cells. Life Sci. 84, 650-656.
48. Katuru, R., N. V. Fernandes, M. Elfakhani, D. Dutta, N. Mills, D. L. Hynds, C. King and H. Mo. 2011. Mevalonate depletion mediates the suppressive impact of geranylgeraniol on murine B16 melanoma cells. Exp. Biol. Med. (Maywood) 236, 604-613.
49. Klein, E. A. et al. 2011. Vitamin E and the risk of prostate cancer. JAMA 306, 1549-1556.
50. Kunnumakkara, A. B. et al. 2010. γ-Tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment. Cancer Res. 70, 8695-8705.
51. Li, X., L. Liu, J. C. Tupper, D. D. Bannerman, R. K. Winn, S. M. Sebti, A. D. Hamilton and J. M. Harlan. 2002. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J. Biol. Chem. 277, 15309-15316.
52. Li, Y., W. G. Sun, H. K. Liu, G. Y. Qi, Q. Wang, X. R. Sun, B. Q. Chen and J. R. Liu. 2011. γ-Tocotrienol inhibits angiogenesis of human umbilical vein endothelia cell induced by cancer cell. J. Nutr. Biochem. 22, 1127-1136.
53. Liu, H. K., Q. Wang, Y. Li, W. G. Sun, J. R. Liu, Y. M. Yang, W. L. Xu, X. R. Sun and B. Q. Chen. 2010. Inhibitory effects of γ-tocotrienol on invasion and metastasis of human gastric adenocarcinoma SGC-7901 cells. J. Nutr. Biochem. 21, 206-213.
54. Luk, S. U. et al. 2011. Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population. Int. J. Cancer 128, 2182-2191.
55. Massague, J. 2004. G1 cell-cycle control and cancer. Nature 432, 298-306.
56. Maurer-Stroh, S., M. Koranda, W. Benetka, G. Schneider, F. L. Sirota and F. Eisenhaber. 2007. Towards complete sets of farnesylated and geranylgeranylated proteins. PLoS Comput. Biol. 3, e66.
57. McAnally, J. A., J. Gupta, S. Sodhani, L. Bravo and H. Mo. 2007. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo. Exp. Biol. Med. (Maywood) 232, 523-531.
58. McCampbell, A. S., R. R. Broaddus, D. S. Loose and P. J. Davies. 2006. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin. Cancer Res. 12, 6373-6378.
59. McIntyre, B. S., K. P. Briski, A. Gapor and P. W. Sylvester. 2000a. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc. Soc. Exp. Biol. Med. 224, 292-301.
60. McIntyre, B. S., K. P. Briski, M. A. Tirmenstein, M. W. Fariss, A. Gapor and P. W. Sylvester. 2000b. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on normal mouse mammary epithelial cells. Lipids 35, 171-180.
61. Meigs, T. E. and R. D. Simoni. 1997. Farnesol as a regulator of HMG-CoA reductase degradation: Characterization and role of farnesyl pyrophosphatase. Arch. Biochem. Biophys. 345, 1-9.
62. de Mesquita, M. L. et al. 2011. Cytotoxicity of δ-tocotrienols from Kielmeyera coriacea against cancer cell lines. Bioorg. Med. Chem. 19, 623-630.
63. Miyazawa, T., A. Shibata, P. Sookwong, Y. Kawakami, T. Eitsuka, A. Asai, S. Oikawa and K. Nakagawa. 2009. Antiangiogenic and anticancer potential of unsaturated vitamin E (tocotrienol). J. Nutr. Biochem. 20, 79-86.
64. Mizukami, Y., H. Ura, T. Obara, A. Habiro, T. Izawa, M. Osanai, N. Yanagawa, S. Tanno and Y. Kohgo. 2001. Requirement of c-jun N-terminal kinase for apoptotic cell death induced by farnesyltransferase inhibitor, farnesylamine, in human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 288, 198-204.
65. Mo, H. and C. E. Elson. 1999. Apoptosis and cell-cycle arrest in human and murine tumor cells are initiated by isoprenoids. J. Nutr. 129, 804-813.
66. Mo, H. and C. E. Elson. 2004. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp. Biol. Med. (Maywood) 229, 567-585.
67. Mo, H. and C. E. Elson. 2008. Role of the mevalonate pathway in tocotrienol-mediated tumor suppression. In Tocotrienols: Vitamin E beyond Tocopherols. eds. R. R. Watson and V. R. Preedy. Boca Raton, FL, CRC Press: pp. 185-207.
68. Moir, R. D., T. P. Spann, R. I. Lopez-Soler, M. Yoon, A. E. Goldman, S. Khuon and R. D. Goldman. 2000. Review: The dynamics of the nuclear lamins during the cell cycle-Relationship between structure and function. J. Struct. Biol. 129, 324-334.
69. Monville, F., L. Gaelle, N. Cervera, J. Wicinskij, J. Geneix, D. Birnbaum and E. Charafe-Jauffret. 2008. Sterol biosynthesis pathway is overexpressed in mammary tumorospheres. Proc. Am. Assoc. Cancer Res., Abs# 2015.
70. Mudit, M., F. A. Behery, V. B. Wali, P. W. Sylvester and K. A. El Sayed. 2010. Synthesis of fluorescent analogues of the anticancer natural products 4-hydroxyphenylmethylene hydantoin and delta-tocotrienol. Nat. Prod. Commun. 5, 1623-1626.
71. Muller, L., K. Theile and V. Bohm. 2010. In vitro antioxidant activity of tocopherols and tocotrienols and comparison of vitamin E concentration and lipophilic antioxidant capacity in human plasma. Mol. Nutr. Food Res. 54, 731-742.
72. Nakagawa, K., A. Shibata, S. Yamashita, T. Tsuzuki, J. Kariya, S. Oikawa and T. Miyazawa. 2007. In vivo angiogenesis is suppressed by unsaturated vitamin E, tocotrienol. J. Nutr. 137, 1938-1943.
73. Nakashima, K., N. Virgona, M. Miyazawa, T. Watanabe and T. Yano. 2010. The tocotrienol-rich fraction from rice bran enhances cisplatin-induced cytotoxicity in human mesothelioma H28 cells. Phytother. Res. 24, 1317-1321.
74. Nesaretnam, K. and P. Meganathan. 2011. Tocotrienols: Inflammation and cancer. Ann. NY Acad. Sci. 1229, 18-22.
75. Nesaretnam, K., P. Meganathan, S. D. Veerasenan and K. R. Selvaduray. 2011. Tocotrienols and breast cancer: The evidence to date. Genes Nutr. 7, 3-9.
76. Nesaretnam, K., K. R. Selvaduray, G. Abdul Razak, S. D. Veerasenan and P. A. Gomez. 2010. Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: A pilot clinical trial. Breast Cancer Res. 12, R81.
77. Nikolic, K. and D. Agababa. 2009. Design and QSAR study of analogs of γ-tocotrienol with enhanced antiproliferative activity against human breast cancer cells. J. Mol. Graph. Model. 27, 777-783.
78. Pallottini, V., B. Guantario, C. Martini, P. Totta, I. Filippi, F. Carraro and A. Trentalance. 2008. Regulation of HMG-CoA reductase expression by hypoxia. J. Cell. Biochem. 104, 701-709.
79. Park, S. K., B. G. Sanders and K. Kline. 2010. Tocotrienols induce apoptosis in breast cancer cell lines via an endoplasmic reticulum stress-dependent increase in extrinsic death receptor signaling. Breast Cancer Res. Treat. 124, 361-375.
80. Parker, R. A., B. C. Pearce, R. W. Clark, D. A. Gordon and J. J. Wright. 1993. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem. 268, 11230-11238.
81. Patacsil, D. et al. 2011. Gamma-tocotrienol induced apoptosis is associated with unfolded protein response in human breast cancer cells. J. Nutr. Biochem. 23, 93-100.
82. Pearce, B. C., R. A. Parker, M. E. Deason, A. A. Qureshi and J. J. Wright. 1992. Hypocholesterolemic activity of synthetic and natural tocotrienols. J. Med. Chem. 35, 3595-3606.
83. Pierpaoli, E., V. Viola, F. Pilolli, M. Piroddi, F. Galli and M. Provinciali. 2010. γ- and δ-tocotrienols exert a more potent anticancer effect than α-tocopheryl succinate on breast cancer cell lines irrespective of HER-2/neu expression. Life Sci. 86, 668-675.
84. Qureshi, A. A., W. C. Burger, D. M. Peterson and C. E. Elson. 1986. The structure of an inhibitor of cholesterol biosynthesis isolated from barley. J. Biol. Chem. 261, 10544-10550.
85. Qureshi, A. A., B. C. Pearce, R. M. Nor, A. Gapor, D. M. Peterson and C. E. Elson. 1996. Dietary α-tocopherol attenuates the impact of γ-tocotrienol on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in chickens. J. Nutr. 126, 389-394.
86. Qureshi, A. A., D. M. Peterson, C. E. Elson, A. R. Mangels and Z. Z. Din. 1989. Stimulation of avian cholesterol metabolism by α-tocopherol. Nutr. Rep. Int. 40, 993-1001.
87. Qureshi, A. A., J. C. Reis, C. J. Papasian, D. C. Morrison and N. Qureshi. 2010. Tocotrienols inhibit lipopolysaccharide-induced pro-inflammatory cytokines in macrophages of female mice. Lipids Health Dis. 9, 143.
88. Rajendran, P., F. Li, K. A. Manu, M. K. Shanmugam, S. Y. Loo, A. P. Kumar and G. Sethi. 2011. γ-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: Potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent. Br. J. Pharmacol. 163, 283-298.
89. Ralhan, R., M. K. Pandey and B. B. Aggarwal. 2009. Nuclear factor-kappa B links carcinogenic and chemopreventive agents. Front. Biosci. (Schol Ed) 1, 45-60.
90. Ramdas, P., M. Rajihuzzaman, S. D. Veerasenan, K. R. Selvaduray, K. Nesaretnam and A. K. Radhakrishnan. 2011. Tocotrienol-treated MCF-7 human breast cancer cells show down-regulation of API5 and up-regulation of MIG6 genes. Cancer Genomics Proteomics 8, 19-31.
91. Saito, Y., K. Nishio, Y. O. Akazawa, K. Yamanaka, A. Miyama, Y. Yoshida, N. Noguchi and E. Niki. 2010. Cytoprotective effects of vitamin E homologues against glutamate-induced cell death in immature primary cortical neuron cultures: Tocopherols and tocotrienols exert similar effects by antioxidant function. Free Radic. Biol. Med. 49, 1542-1549.
92. Samant, G. V., V. B. Wali and P. W. Sylvester. 2010. Anti-proliferative effects of γ-tocotrienol on mammary tumour cells are associated with suppression of cell cycle progression. Cell Prolif. 43, 77-83.
93. Selvaduray, K. R., A. K. Radhakrishnan, M. K. Kutty and K. Nesaretnam. 2010. Palm tocotrienols inhibit proliferation of murine mammary cancer cells and induce expression of interleukin-24 mRNA. J. Interferon Cytokine Res. 30, 909-916.
94. Sherr, C. J. 2004. Principles of tumor suppression. Cell 116, 235-246.
95. Shibata, A., K. Nakagawa, P. Sookwong, T. Tsuduki, A. Asai and T. Miyazawa. 2010. α-Tocopherol attenuates the cytotoxic effect of δ-tocotrienol in human colorectal adenocarcinoma cells. Biochem. Biophys. Res. Commun. 397, 214-219.
96. Shibata, A., K. Nakagawa, P. Sookwong, T. Tsuduki, S. Oikawa and T. Miyazawa. 2009. δ-Tocotrienol suppresses VEGF induced angiogenesis whereas α-tocopherol does not. J. Agric. Food Chem. 57, 8696-8704.
97. Shibata, A., K. Nakagawa, P. Sookwong, T. Tsuzuki, S. Oikawa and T. Miyazawa. 2008a. Tumor anti-angiogenic effect and mechanism of action of δ-tocotrienol. Biochem. Pharmacol. 76, 330-339.
98. Shibata, A., K. Nakagawa, P. Sookwong, T. Tsuduki, S. Tomita, H. Shirakawa, M. Komai and T. Miyazawa. 2008b. Tocotrienol inhibits secretion of angiogenic factors from human colorectal adenocarcinoma cells by suppressing hypoxia-inducible factor-1α. J. Nutr. 138, 2136-2142.
99. Shin-Kang, S., V. P. Ramsauer, J. Lightner, K. Chakraborty, W. Stone, S. Campbell, S. A. Reddy and K. Krishnan. 2011. Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway. Free Radic. Biol. Med. 51, 1164-1174.
100. Shirode, A. B. and P. W. Sylvester. 2010. Synergistic anticancer effects of combined γ-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFκB signaling. Biomed. Pharmacother. 64, 327-332.
101. Song, B. L. and R. A. DeBose-Boyd. 2006. Insig-dependent ubiquitination and degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase stimulated by δ- and γ-tocotrienols. J. Biol. Chem. 281, 25054-25061.
102. Springett, G. M., A. M. Neuger, B. A. Centeno, T. Hutchinson, H. Jump, R. Lush, S. Sebti and M. P. Malafa. 2011. A phase I dose-escalation study of the safety, PK, and PD of vitamin E δ-tocotrienol administered to subjects with resectable pancreatic exocrine neoplasia. Proc. Am. Assoc. Cancer Res. 52, Abs# 1299.
103. Sun, W., Q. Wang, B. Chen, J. Liu, H. Liu and W. Xu. 2008. γ-Tocotrienol-induced apoptosis in human gastric cancer SGC-7901 cells is associated with a suppression in mitogen-activated protein kinase signalling. Br. J. Nutr. 99, 1247-1254.
104. Sun, W., W. Xu, H. Liu, J. Liu, Q. Wang, J. Zhou, F. Dong and B. Chen. 2009. γ-Tocotrienol induces mitochondria-mediated apoptosis in human gastric adenocarcinoma SGC-7901 cells. J. Nutr. Biochem. 20, 276-284.
105. Sylvester, P. W. 2011. Synergistic anticancer effects of combined γ-tocotrienol with statin or receptor tyrosine kinase inhibitor treatment. Genes Nutr. 7, 63-74.
106. Sylvester, P. W., V. B. Wali, S. V. Bachawal, A. B. Shirode, N. M. Ayoub and M. R. Akl. 2011. Tocotrienol combination therapy results in synergistic anticancer response. Front. Biosci. 17, 3183-3195.
107. Takada, Y., F. R. Khuri and B. B. Aggarwal. 2004. Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-κB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-κB-regulated gene expression and up-regulation of apoptosis. J. Biol. Chem. 279, 26287-26299.
108. Tasaki, M., T. Umemura, T. Inoue, T. Okamura, Y. Kuroiwa, Y. Ishii, M. Maeda, M. Hirose and A. Nishikawa. 2008. Induction of characteristic hepatocyte proliferative lesion with dietary exposure of Wistar Hannover rats to tocotrienol for 1 year. Toxicology 250, 143-150.
109. Ura, H., T. Obara, R. Shudo, A. Itoh, S. Tanno, T. Fujii, N. Nishino and Y. Kohgo. 1998. Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts. Mol. Carcinog. 21, 93-99.
110. Venkatasubbarao, K., A. Choudary and J. W. Freeman. 2005. Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases. Cancer Res. 65, 2861-2871.
111. Wali, V. B., S. V. Bachawal and P. W. Sylvester. 2009a. Combined treatment of γ-tocotrienol with statins induce mammary tumor cell cycle arrest in G1. Exp. Biol. Med. (Maywood) 234, 639-650.
112. Wali, V. B., S. V. Bachawal and P. W. Sylvester. 2009b. Endoplasmic reticulum stress mediates γ-tocotrienolinduced apoptosis in mammary tumor cells. Apoptosis 14, 1366-1377.
113. Wali, V. B., S. V. Bachawal and P. W. Sylvester. 2009c. Suppression in mevalonate synthesis mediates antitumor effects of combined statin and γ-tocotrienol treatment. Lipids 44, 925-934.
114. Wang, W., J. L. Abbruzzese, D. B. Evans, L. Larry, K. R. Cleary and P. J. Chiao. 1999. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 5, 119-127.
115. Weisz, B., K. Giehl, M. Gana-Weisz, Y. Egozi, G. Ben-Baruch, D. Marciano, P. Gierschik and Y. Kloog. 1999. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 18, 2579-2588.
116. Weng-Yew, W., K. R. Selvaduray, C. H. Ming and K. Nesaretnam. 2009. Suppression of tumor growth by palm tocotrienols via the attenuation of angiogenesis. Nutr. Cancer 61, 367-373.
117. Wu, S. J., P. L. Liu and L. T. Ng. 2008. Tocotrienol-rich fraction of palm oil exhibits anti-inflammatory property by suppressing the expression of inflammatory mediators in human monocytic cells. Mol. Nutr. Food Res. 52, 921-929.
118. Wu, S. J. and L. T. Ng. 2010. Tocotrienols inhibited growth and induced apoptosis in human HeLa cells through the cell cycle signaling pathway. Integr. Cancer Ther. 9, 66-72.
119. Xu, W., M. Du, Y. Zhao, Q. Wang, W. Sun and B. Chen. γ-Tocotrienol inhibits cell viability through suppression of β-catenin/Tcf signaling in human colon carcinoma HT-29 cells. J. Nutr. Biochem. (in press).
120. Xu, W. L., J. R. Liu, H. K. Liu, G. Y. Qi, X. R. Sun, W. G. Sun and B. Q. Chen. 2009. Inhibition of proliferation and induction of apoptosis by γ-tocotrienol in human colon carcinoma HT-29 cells. Nutrition 25, 555-566.
121. Yang, Z., H. Xiao, H. Jin, P. T. Koo, D. J. Tsang and C. S. Yang. 2010. Synergistic actions of atorvastatin with γ-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells. Int. J. Cancer 126, 852-863.
122. Yap, W. N., P. N. Chang, H. Y. Han, D. T. W. Lee, M. T. Ling, Y. C. Wong and Y. L. Yap. 2008. γ-Tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. Br. J. Cancer 99, 1832-1841.
123. Yap, S. P., K. H. Yuen and J. W. Wong. 2001. Pharmacokinetics and bioavailability of α-, γ- and δ-tocotrienols under different food status. J. Pharm. Pharmacol. 53, 67-71.
124. Yap, W. N., N. Zaiden, S. Y. Luk, D. T. Lee, M. T. Ling, Y. C. Wong and Y. L. Yap. 2010a. In vivo evidence of γ-tocotrienol as a chemosensitizer in the treatment of hormone-refractory prostate cancer. Pharmacology 85, 248-258.
125. Yap, W. N., N. Zaiden, Y. L. Tan, C. P. Ngoh, X. W. Zhang, Y. C. Wong, M. T. Ling and Y. L. Yap. 2010b. Id1, inhibitor of differentiation, is a key protein mediating anti-tumor responses of gamma-tocotrienol in breast cancer cells. Cancer Lett. 291, 187-199.
126. Yoshida, Y., E. Niki and N. Noguchi. 2003. Comparative study on the action of tocopherols and tocotrienols as antioxidant: Chemical and physical effects. Chem. Phys. Lipids 123, 63-75.
127. Yu, W., M. Simmons-Menchaca, A. Gapor, B. G. Sanders and K. Kline. 1999. Induction of apoptosis in human breast cancer cells by tocopherols and tocotrienols. Nutr. Cancer 33, 26-32.
128. Zhang, F. L. and P. J. Casey. 1996. Protein prenylation: Molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65, 241-269.
129. Zhang, J. S., D. M. Li, N. He, Y. H. Liu, C. H. Wang, S. Q. Jiang, B. Q. Chen and J. R. Liu. 2011. A paraptosislike cell death induced by δ-tocotrienol in human colon carcinoma SW620 cells is associated with the suppression of the Wnt signaling pathway. Toxicology 285, 8-17.